544 related articles for article (PubMed ID: 31345626)
21. NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer.
Viswanathan AN; Moughan J; Miller BE; Xiao Y; Jhingran A; Portelance L; Bosch WR; Matulonis UA; Horowitz NS; Mannel RS; Souhami L; Erickson BA; Winter KA; Small W; Gaffney DK
Cancer; 2015 Jul; 121(13):2156-63. PubMed ID: 25847373
[TBL] [Abstract][Full Text] [Related]
22. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Haddad R; O'Neill A; Rabinowits G; Tishler R; Khuri F; Adkins D; Clark J; Sarlis N; Lorch J; Beitler JJ; Limaye S; Riley S; Posner M
Lancet Oncol; 2013 Mar; 14(3):257-64. PubMed ID: 23414589
[TBL] [Abstract][Full Text] [Related]
23. Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S; Scambia G; Schettino C; Arenare L; Pisano C; Lombardi D; De Giorgi U; Andreetta C; Cinieri S; De Angelis C; Priolo D; Casanova C; Rosati M; Greco F; Zafarana E; Schiavetto I; Mammoliti S; Cecere SC; Salutari V; Scalone S; Farolfi A; Di Napoli M; Lorusso D; Gargiulo P; Califano D; Russo D; Spina A; De Cecio R; Chiodini P; Perrone F;
Lancet Oncol; 2023 Mar; 24(3):286-296. PubMed ID: 37052965
[TBL] [Abstract][Full Text] [Related]
24. Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer.
Milgrom SA; Kollmeier MA; Abu-Rustum NR; Tew WP; Sonoda Y; Barakat RR; Alektiar KM
Gynecol Oncol; 2013 Sep; 130(3):436-40. PubMed ID: 23800696
[TBL] [Abstract][Full Text] [Related]
25. Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.
Monk BJ; Toita T; Wu X; Vázquez Limón JC; Tarnawski R; Mandai M; Shapira-Frommer R; Mahantshetty U; Del Pilar Estevez-Diz M; Zhou Q; Limaye S; Godinez FJR; Oppermann Kussler C; Varga S; Valdiviezo N; Aoki D; Leiva M; Lee JY; Sulay R; Kreynina Y; Cheng WF; Rey F; Rong Y; Ke G; Wildsmith S; Lloyd A; Dry H; Tablante Nunes A; Mayadev J
Lancet Oncol; 2023 Dec; 24(12):1334-1348. PubMed ID: 38039991
[TBL] [Abstract][Full Text] [Related]
26. Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01).
Penniment MG; De Ieso PB; Harvey JA; Stephens S; Au HJ; O'Callaghan CJ; Kneebone A; Ngan SY; Ward IG; Roy R; Smith JG; Nijjar T; Biagi JJ; Mulroy LA; Wong R;
Lancet Gastroenterol Hepatol; 2018 Feb; 3(2):114-124. PubMed ID: 29248399
[TBL] [Abstract][Full Text] [Related]
27. Sequential Chemoradiotherapy Compared to Radiotherapy in Endometrial Carcinoma.
Elemam O; Abdelkhalek S; Abdelmoety D; Aboelnaga E; Baraka R; Zeeneldine A
Asian Pac J Cancer Prev; 2020 May; 21(5):1327-1332. PubMed ID: 32458640
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant radiotherapy for stage I endometrial cancer.
Kong A; Johnson N; Kitchener HC; Lawrie TA
Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD003916. PubMed ID: 22513918
[TBL] [Abstract][Full Text] [Related]
29. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer.
Randall ME; Filiaci V; McMeekin DS; von Gruenigen V; Huang H; Yashar CM; Mannel RS; Kim JW; Salani R; DiSilvestro PA; Burke JJ; Rutherford T; Spirtos NM; Terada K; Anderson PR; Brewster WR; Small W; Aghajanian CA; Miller DS
J Clin Oncol; 2019 Jul; 37(21):1810-1818. PubMed ID: 30995174
[TBL] [Abstract][Full Text] [Related]
30. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
Alektiar KM; Venkatraman E; Chi DS; Barakat RR
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
[TBL] [Abstract][Full Text] [Related]
31. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Clamp AR; James EC; McNeish IA; Dean A; Kim JW; O'Donnell DM; Gallardo-Rincon D; Blagden S; Brenton J; Perren TJ; Sundar S; Lord R; Dark G; Hall M; Banerjee S; Glasspool RM; Hanna CL; Williams S; Scatchard KM; Nam H; Essapen S; Parkinson C; McAvan L; Swart AM; Popoola B; Schiavone F; Badrock J; Fananapazir F; Cook AD; Parmar M; Kaplan R; Ledermann JA
Lancet Oncol; 2022 Jul; 23(7):919-930. PubMed ID: 35690073
[TBL] [Abstract][Full Text] [Related]
32. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Bosset JF; Calais G; Mineur L; Maingon P; Stojanovic-Rundic S; Bensadoun RJ; Bardet E; Beny A; Ollier JC; Bolla M; Marchal D; Van Laethem JL; Klein V; Giralt J; Clavère P; Glanzmann C; Cellier P; Collette L;
Lancet Oncol; 2014 Feb; 15(2):184-90. PubMed ID: 24440473
[TBL] [Abstract][Full Text] [Related]
33. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Chen L; Hu CS; Chen XZ; Hu GQ; Cheng ZB; Sun Y; Li WX; Chen YY; Xie FY; Liang SB; Chen Y; Xu TT; Li B; Long GX; Wang SY; Zheng BM; Guo Y; Sun Y; Mao YP; Tang LL; Chen YM; Liu MZ; Ma J
Lancet Oncol; 2012 Feb; 13(2):163-71. PubMed ID: 22154591
[TBL] [Abstract][Full Text] [Related]
34. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Pignata S; Lorusso D; Joly F; Gallo C; Colombo N; Sessa C; Bamias A; Salutari V; Selle F; Frezzini S; De Giorgi U; Pautier P; Bologna A; Orditura M; Dubot C; Gadducci A; Mammoliti S; Ray-Coquard I; Zafarana E; Breda E; Favier L; Ardizzoia A; Cinieri S; Largillier R; Sambataro D; Guardiola E; Lauria R; Pisano C; Raspagliesi F; Scambia G; Daniele G; Perrone F;
Lancet Oncol; 2021 Feb; 22(2):267-276. PubMed ID: 33539744
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics.
Young MR; Higgins SA; Ratner E; Yu JB; Mani S; Silasi DA; Azodi M; Rutherford T; Schwartz PE; Damast S
Int J Gynecol Cancer; 2015 Mar; 25(3):431-9. PubMed ID: 25621409
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Shapiro J; van Lanschot JJB; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch ORC; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Bilgen EJS; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A;
Lancet Oncol; 2015 Sep; 16(9):1090-1098. PubMed ID: 26254683
[TBL] [Abstract][Full Text] [Related]
37. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.
Kunkler IH; Williams LJ; Jack WJ; Cameron DA; Dixon JM;
Lancet Oncol; 2015 Mar; 16(3):266-73. PubMed ID: 25637340
[TBL] [Abstract][Full Text] [Related]
38. One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT.
Brunt AM; Haviland JS; Wheatley DA; Sydenham MA; Bloomfield DJ; Chan C; Cleator S; Coles CE; Donovan E; Fleming H; Glynn D; Goodman A; Griffin S; Hopwood P; Kirby AM; Kirwan CC; Nabi Z; Patel J; Sawyer E; Somaiah N; Syndikus I; Venables K; Yarnold JR; Bliss JM;
Health Technol Assess; 2023 Nov; 27(25):1-176. PubMed ID: 37991196
[TBL] [Abstract][Full Text] [Related]
39. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Hofheinz RD; Wenz F; Post S; Matzdorff A; Laechelt S; Hartmann JT; Müller L; Link H; Moehler M; Kettner E; Fritz E; Hieber U; Lindemann HW; Grunewald M; Kremers S; Constantin C; Hipp M; Hartung G; Gencer D; Kienle P; Burkholder I; Hochhaus A
Lancet Oncol; 2012 Jun; 13(6):579-88. PubMed ID: 22503032
[TBL] [Abstract][Full Text] [Related]
40. Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer.
Greven K; Winter K; Underhill K; Fontenesci J; Cooper J; Burke T;
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):168-73. PubMed ID: 15093913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
